Primer on medical genomics part VI: Genomics and molecular genetics in clinical practice

Mayo Clinic Proceedings

Volumn 78, Issue 3, 2003, Pages 307-317

  Ansell, Stephen M ^a   Ackerman, Michael J ^a   Black, John L ^a   Roberts, Lewis R ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GENE PRODUCT; RNA;

ARTICLE; CLINICAL PRACTICE; DIAGNOSTIC VALUE; DRUG TOXICITY; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC PROCEDURES; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; GENOMICS; HIGH RISK POPULATION; HUMAN; HUMAN GENOME; MOLECULAR GENETICS; OUTCOMES RESEARCH; PREDICTION; PROGNOSIS; REGULATOR GENE; RISK ASSESSMENT; TECHNIQUE;

EID: 0037373160     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.3.307     Document Type: Article

References (84)

1. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell. 2001;104:569-580.
2. Ackerman MJ. The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc. 1998;73:250-269.
3. Seidman CE, Seidman JG. Molecular genetic studies of familial hypertrophic cardiomyopathy. Basic Res Cardiol. 1998;93(suppl 3):13-16.
4. Ackerman MJ, Clapham DE. Ion channels - basic science and clinical disease. N Engl J Med. 1997;336:1575-1586.
5. Ackerman MJ, Tester DJ, Porter CJ, Edwards WD. Molecular diagnosis of the inherited long-QT syndrome in a woman who died after near-drowning. N Engl J Med. 1999;341:1121-1125.
6. Ackerman MJ, Siu BL, Sturner WQ, et al. Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA. 2001;286:2264-2269.
7. Marcus PM, Hayes RB, Vineis P, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev. 2000;9:461-467.
8. Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics. 2000;10:115-122.
9. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481-1487.
10. Romero Y, Cameron AJ, Locke GR III, et al. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 1997;113:1449-1456.
11. Trudgill NJ, Kapur KC, Riley SA. Familial clustering of reflux symptoms. Am J Gastroenterol. 1999;94:1172-1178.
12. Cameron AJ, Lagergren J, Henriksson C, Nyren O, Locke GR III, Pedersen NL. Gastroesophageal reflux disease in monzygotic and dizygotic twins. Gastroenterology. 2002;122:55-59.
13. Romero Y, Cameron AJ, Burgart LJ, et al. Family history doubles Barrett's esophagus risk. Dig Dis Week. 2002.
14. Zais TG, Romero Y, Vazquez-Sequeiros E, et al. Barrett's esophagus genomic study group: examples of high prevalence Barrett's esophagus families [abstract]. Am J Gastroenterol. 2001;96(suppl): S45. Abstract 140.
15. Altmüller J, Palmer LJ, Fischer G, Scherb H, Wjst M. Genomewide scans of complex human diseases: true linkage is hard to find. Am J Hum Genet. 2001;69:936-950.
16. Meyer J, Huberth A, Ortega G, et al. A missense mutation in a novel gene encoding a putative cation channel is associated with catatonic schizophrenia in a large pedigree. Mol Psychiatry. 2001; 6:302-306.
17. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001;3:139-148.
18. Butler R. The DD-ACE genotype and cardiovascular disease. Pharmacogenomics. 2000;1: 153-167.
19. Gusterson BA, Machin LG, Gullick WJ, et al. Immunohistochemical distribution of c-erB-2 in infiltrating and in situ breast cancer. Int J Cancer. 1988;42:842-845.
20. Paik S, Hazan R, Fisher ER, et al. Pathological findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8:103-112.
21. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
22. Bems EM, Foekens JA, van Staveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene. 1995;159:11-18.
23. Fox SB, Smith K, Hollyer J, et al. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat. 1994;29:41-49.
24. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415:530-536.
25. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
26. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
27. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
28. Krishnadath KK, Wang KK, Sebo TJ, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology. 2000; 119:624-630.
29. Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D. Light-directed, spatially addressable parallel chemical synthesis. Science. 1991;251:767-773.
30. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol. 2002; 160:641-654.
31. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut. 2001;49:565-576.
32. Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001;61:2129-2137.
33. Nielsen DA, Goldman D, Virkkunen M, Tokola R, Rawlings R, Linnoila M. Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism. Arch Gen Psychiatry. 1994;51:34-38.
34. Nielsen DA, Virkkunen M, Lappalainen J, et al. A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry. 1998;55:593-602.
35. Roy A, Rylander G, Forslund K, et al. Excess tryptophan hydroxylase 17 779C allele in surviving cotwins of monozygotic twin suicide victims. Neuropsychobiology. 2001;43:233-236.
36. Rotondo A, Schuebel K, Bergen A, et al. Identification of four variants in the tryptophan hydroxylase promoter and association to behavior. Mol Psychiatry. 1999;4:360-368.
37. Tsai SJ, Hong CJ, Wang YC. Tryptophan hydroxylase gene polymorphism (A218C) and suicidal behaviors. Neuroreport. 1999;10: 3773-3775.
38. Paik I, Toh K, Kim J, Lee C. TPH gene may be associated with suicidal behavior, but not with schizophrenia in the Korean population. Hum Hered. 2000;50:365-369.
39. Turecki G, Zhu Z, Tzenova J, et al. TPH and suicidal behavior: a study in suicide completers. Mol Psychiatry. 2001;6:98-102.
40. Souery D, Van Gestel S, Massat I, et al. Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study. Biol Psychiatry. 2001; 49:405-409.
41. Abbar M, Courtet P, Bellivier F, et al. Suicide attempts and the tryptophan hydroxylase gene. Mol Psychiatry. 2001;6:268-273.
42. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527-1531.
43. Du L, Faludi G, Palkovits M, et al. Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims. Biol Psychiatry. 1999;46:196-201.
44. Bellivier F, Szoke A, Henry C, et al. Possible association between serotonin transporter gene polymorphism and violent suicidal behavior in mood disorders. Biol Psychiatry. 2000;48:319-322.
45. Bondy B, Erfurth A, de Jonge S, Kruger M, Meyer H. Possible association of the short allele of the serotonin transporter promoter gene polymorphism (5-HTTLPR) with violent suicide. Mol Psychiatry. 2000;5:193-195.
46. Gorwood P, Batel P, Ades J, Hamon M, Boni C. Serotonin transporter gene polymorphisms, alcoholism, and suicidal behavior. Biol Psychiatry. 2000;48:259-264.
47. New AS, Gelernter J, Goodman M, et al. Suicide, impulsive aggression, and HTR1B genotype. Biol Psychiatry. 2001;50:62-65.
48. Nishiguchi N, Shirakawa O, Ono H, et al. No evidence of an association between 5HT1B receptor gene polymorphism and suicide victims in a Japanese population. Am J Med Genet, 2001;105: 343-345.
49. Cao L, Li T, Xu K, Liu X. Association analysis of attempted suicide and 5-HT2A receptor gene [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2001;18:195-197.
50. 2A receptor gene polymorphism in mood disorders. Biol Psychiatry. 1997;41:768-773.
51. Ono H, Shirakawa O, Nishiguchi N, et al. Serotonin 2A receptor gene polymorphism is not associated with completed suicide. J Psychiatr Res. 2001;35:173-176.
52. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension. 2001;37:739-743.
53. Psaty BM, Smith NL, Heckbert SR, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA. 2002;287: 1680-1689.
54. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105:1943-1948.
55. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia [abstract]. Science. 1960;132:1497.
56. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature. 1973,243:290-293.
57. Melo JV. The molecular biology of chronic myeloid leukaemia. Leukemia. 1996;10:751-756.
58. Abelson HT, Rabstein LS. Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res. 1970;30:2213-2222.
59. Witte ON, Goff S, Rosenberg N, Baltimore D. A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity. Proc Proe Natl Acad Sci U S A. 1980;77:4993-4997.
60. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.
61. Druker BJ. Current treatment approaches for chronic myelogenous leukemia. Cancer J. 2001;7(suppl 1):S14-S18.
62. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
63. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
64. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1084-1086.
65. Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev. 2001;21:499-512.
66. Fenaux P, Chastang C, Chevret S, et al, European APL Group. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:1192-1200.
67. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000; 24:227-235.
68. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989;9:1165-1172.
69. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother. 1993;37:255-263.
70. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
71. Targan SR, Hanauer SB, van Deventer SJ, et al, Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
72. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
73. Sandbom WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001;120:1330-1338.
74. Feagan BG, Sandbom WJ, Baker JP, et al. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease [abstract]. Gastroenterology. 2000;118(suppl 2):A655. Abstract 3599.
75. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001;121: 268-274.
76. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662.
77. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000; 118:1025-1030.
78. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology, 2000;118:705-713.
79. Honda M, Orii F, Ayabe T, et al. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology. 2000;118:859-866.
80. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology. 2000;118:279-288.
81. Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl. 1997;391: 14-21.
82. Løvlie R, Daly AK, Matre GE, Molven A, Steen VM. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics. 2001;11:45-55.
83. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand, 2001;104:173-192.
84. Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol. 2000;10:27-34.